Shanghai Kehui Baisheng

Leader in Nanobody Drug Development

Focus on nanobody development, interaction screening and targeted antibody manufacturing, empowering biomedical innovation

Learn Our Technology

Ultra-large Library Capacity Screening

Use in vitro screening platform to reduce from 10^15 to 10^9 covered by phage

Efficient Screening Technology

High-throughput interaction screening, reducing development cycle by 75%

Customized Service

Customize different nanobody scaffolds, including but not limited to centyrin, CH3, humanized, oral scaffolds

Products

Nanobody Drug Product Line

Humanized Nanobody Library Screening

Directly use humanized scaffolds to build nanobody libraries, screened molecules are final molecules, improving success rate and shortening cycles.

查看详情

Oral Nanobody Screening

Directly use humanized + anti-gastric and intestinal protease degradation scaffolds to build nanobody libraries, while optimizing CDR sequence composition, screened molecules can be directly used for subsequent oral drug development

查看详情

Masking Peptide Screening

Peptide drug screening, TCE masking peptide screening, ultra-large library capacity rapid screening, more flexible and concise than DEL, lower cost and shorter time.

查看详情

View All Products

Research Strength

Proprietary nanobody development platform integrating phage display technology and high-throughput screening systems, average development cycle reduced by 75%.

75%

Development Cycle Reduced

50%

Project Cost Reduced

100000+

Screening Library Capacity

100%

Data Delivery Rate